You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 132 No. 8, August 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Reduction in Costs, Blood Products, and Operating Time in Patients Undergoing Open Heart Surgery

Robert R. Lazzara, MD; Francis E. Kidwell; Michael F. Kraemer, CCP; James A. Wood, MD; Albert Starr, MD

Arch Surg. 1997;132(8):858-861.


Abstract

Objective
To test the hypothesis that use of aprotinin at half dose would be more cost-effective or as efficacious as full-dose aprotinin or no aprotinin during open heart surgery.

Design
Cost-effective analysis, unmasked prospective comparison.

Setting
Community hospital.

Patients
One hundred thirty-three patients undergoing open heart surgery.

Interventions
Patients in 3 consecutive groups undergoing open heart surgery were allocated to receive no aprotinin, full-dose aprotinin, or half-dose aprotinin.

Main Outcome Measures
Total cost (in dollars) of blood products administered plus cost of aprotinin at various dosages, comparison of total blood products administered during hospitalization, and closure time required in the operating room.

Results
Full-dose and half-dose aprotinin significantly (P<.05) reduced the total blood products administered during hospitalization and the operating room closure time. However, use of half-dose aprotinin resulted in a significant cost savings (P<.05) when compared with either the cost of blood products required in the nodose aprotinin group or the cost of blood products plus aprotinin in the full-dose aprotinin group.

Conclusion
Use of aprotinin at half dose in a community hospital resulted in a significant reduction in costs, blood product use, and operating room closure time in patients undergoing open heart surgery.

Arch Surg. 1997;132:858-861



Author Affiliations

From the Division of Cardiac Surgery, St Charles Medical Center, Bend, Ore, and The Albert Starr Institute for Academic Cardiac Surgery, Portland, Ore.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials
Smith et al.
Ann. Thorac. Surg. 2004;77:635-642.
ABSTRACT | FULL TEXT  

Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations
Dignan et al.
Ann. Thorac. Surg. 2001;71:158-164.
ABSTRACT | FULL TEXT  

Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass
Ray et al.
Ann. Thorac. Surg. 1999;68:940-945.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.